# Rouge Therapeutics funding rounds and investors

As of 22 Nov 2026, Rouge Therapeutics has raised $58M across 1 verified round on record; latest: $58 million Series A led by Angelini Ventures, BioGeneration Ventures and 1 other, announced 6 Oct 2026.

A provider of first-in-class disease-modifying therapies designed to restore vascular integrity

Website: https://www.rougetx.com/  
Headquarters: Naarden, the Netherlands  
Page: https://fireround.dev/companies/rougetx

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-10-06 | Series A | $58 million | Angelini Ventures, BioGeneration Ventures, Kurma Partners | Epidarex Capital, Kerna Ventures, p53 Invest, ROM Utrecht Region, Vesalius Biocapital Partners | [rougetx.com](https://rougetx.com/rougetx-launches-with-58-million-series-a-financing-to-advance-first-in-class-treatment-for-hereditary-hemorrhagic-telangiectasia), [globenewswire.com](https://www.globenewswire.com/en/news-release/2026/10/06/3375146/0/en/rougetx-launches-with-58-million-series-a-financing-to-advance-first-in-class-treatment-for-hereditary-hemorrhagic-telangiectasia.html), [globenewswire.com](https://www.globenewswire.com/fr/news-release/2026/10/06/3375142/0/en/angelini-ventures-and-eib-co-lead-58-million-series-a-financing-in-rouge-therapeutics-to-advance-first-in-class-treatment-for-hereditary-hemorrhagic-telangiectasia.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.
